Publication: A retrospective analysis of 65 patients with acrodermatitis continua of Hallopeau
2
0
Issued Date
2024-03-01
Resource Type
ISSN
09066705
eISSN
16000625
Scopus ID
2-s2.0-85188419865
Pubmed ID
38519437
Journal Title
Experimental Dermatology
Volume
33
Issue
3
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental Dermatology Vol.33 No.3 (2024)
Suggested Citation
Chularojanamontri L., Silpa-Archa N., Pattamadilok B., Julanon N., Chuamanochan M., Pongcharoen P., Lertphanichkul C., Asawanonda P. A retrospective analysis of 65 patients with acrodermatitis continua of Hallopeau. Experimental Dermatology Vol.33 No.3 (2024). doi:10.1111/exd.15055 Retrieved from: https://hdl.handle.net/20.500.14740/20105
Corresponding Author(s)
Other Contributor(s)
Abstract
There are limited data on acrodermatitis continua of Hallopeau (ACH), particularly among Asian populations. The primary aim was to evaluate the clinical features of ACH and treatment approaches in a sizeable multicentre Asian cohort. We analysed data from adult patients diagnosed with ACH. Of 65 patients with ACH, seven patients had ACH with GPP. Females were more frequently affected in both conditions. Five (71.4%) developed GPP 5–33 years after ACH onset, while two (28.6%) developed GPP concurrently with ACH. The onset age for ACH with GPP (27.9 ± 13.6 years) was earlier than that of isolated ACH (39.8 ± 17.3 years). Metabolic comorbidities were common. ACH exhibited a chronic persistent course. Among systemic non-biologics, acitretin was the most frequently prescribed, followed by ciclosporin and methotrexate. Acitretin and ciclosporin demonstrated similar marked response rates, which surpassed that of methotrexate. Regarding biologics, a marked response was more commonly observed with interleukin-17 inhibitors than with tumour necrosis factor inhibitors. Females are predominant in both conditions. The onset age for ACH among Asian patients is earlier (late 30s) than that for Caucasian patients (late 40s). Interleukin-17 inhibitors may be more effective than tumour necrosis factor inhibitors in managing ACH.